Treatment of Paraneoplastic Visual Loss With Intravenous Immunoglobulin
Report of 3 Cases
John Guy, MD;
Nata Aptsiauri, MD, PhD
Arch Ophthalmol. 1999;117:471-477.
Background Paraneoplastic visual loss is an autoimmune disorder believed to be caused by the remote effects of cancer on the retina (cancer-associated retinopathy [CAR]) or optic nerve. Both disorders may result in rapid and complete blindness. Spontaneous recovery of vision has not been reported. The serum of patients with CAR contains autoantibodies against recoverin, enolase, or unidentified retinal proteins. Autopsy examination results of eyes of blind patients with CAR show complete absence of the retinal neurons involved in phototransduction. Corticosteroids and plasmapheresis are the only treatment options previously described.
Objective To treat paraneoplastic visual loss.
Design and Methods Three patients with metastatic cancer developed rapidly progressive loss of vision. The first patient had visual acuity of hand movements in each eye before intravenous immunoglobulin treatment. The second patient had visual acuity of light perception in both eyes. The third patient's visual acuity was 20/400 OD and 20/20 OS. Diagnostic tests included magnetic resonance imaging of the head and cytologic examination of the cerebrospinal fluid to exclude metastasis as the cause of visual loss and then an electroretinogram and serum tests for autoantibodies against retinal antigens to confirm the clinical diagnosis of CAR. Patients 1 and 2 were treated with intravenous immunoglobulin (400 mg/kg per day) for 5 days; however, patient 3 received only a single dose due to adverse effects consisting of shortness of breath and itching.
Results Within 24 hours of taking the first dose of intravenous immunoglobulin, the visual acuity of patient 1 improved from hand movements only in both eyes to 20/50 OD and 20/200 OS. After the third day of treatment, visual acuity in the left eye further improved to 20/40. Even with the improved acuity, Goldmann visual field perimetry results showed poor responses in both eyes. However, 2 weeks later there was marked visual field improvement, and visual acuity was maintained at 20/50 OD and 20/40 OS. Patient 2 had no improvements and continued to have light perception in both eyes. Patient 3 had improvements in visual field defects but remained 20/400 OD and 20/20 OS.
Conclusion Intravenous immunoglobulin may be another treatment option offered to patients with paraneoplastic visual loss in addition to corticosteroids or plasmapheresis because a review of the medical literature has shown no spontaneous improvements of visual function without treatment.
From the Departments of Ophthalmology (Drs Guy and Aptsiauri) and Neurology (Dr Guy), University of Florida, College of Medicine, Gainesville.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 1999;117(4):555.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Management of Autoimmune Retinopathies With Immunosuppression
Ferreyra et al.
Arch Ophthalmol 2009;127:390-397.
ABSTRACT
| FULL TEXT
Immunosuppression for Autoimmune Retinopathy
Jampol and Fishman
Arch Ophthalmol 2009;127:573-575.
FULL TEXT
Increased 18F-FDG Uptake in the Posterior Ocular Bulb Is Associated with Brain Metastasis: A Retrospective Study
Nguyen et al.
Am. J. Roentgenol. 2008;191:W268-W274.
ABSTRACT
| FULL TEXT
Immunomodulatory treatment trial for paraneoplastic neurological disorders
Vernino et al.
Neuro Oncol 2004;6:55-62.
ABSTRACT
Retinopathies Associated with Antiretinal Antibodies
Hooks et al.
CVI 2001;8:853-858.
FULL TEXT
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
Noseworthy et al.
Neurology 2001;56:1514-1522.
ABSTRACT
| FULL TEXT
Cancer-Associated Retinopathy
Goldstein et al.
Arch Ophthalmol 1999;117:1641-1645.
ABSTRACT
| FULL TEXT
|
